CDK4 and breast carcinoma: We show sensitivity to various clinically approved inhibitors, including CDK4/6 inhibitor ribociclib, which is a standard-of-care therapy in the treatment of metastatic ERα-positive breast cancer [20,21,22,23] and currently under evaluation in the neoadjuvant setting [24,25].